Shopping Cart
Remove All
Your shopping cart is currently empty
Glecirasib (JAB-21822) is an orally active KRAS G12C inhibitor that selectively binds to and inhibits the activity of KRAS G12C mutants, thereby inhibiting KRAS G12C-dependent signaling. In animal models, KRAS G12C inhibitor 36 showed a favorable safety profile and potential to inhibit tumor growth.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $113 | - | In Stock | |
| 5 mg | $278 | - | In Stock | |
| 10 mg | $419 | - | In Stock | |
| 25 mg | $637 | - | In Stock | |
| 50 mg | Preferential | - | In Stock |
| Description | Glecirasib (JAB-21822) is an orally active KRAS G12C inhibitor that selectively binds to and inhibits the activity of KRAS G12C mutants, thereby inhibiting KRAS G12C-dependent signaling. In animal models, KRAS G12C inhibitor 36 showed a favorable safety profile and potential to inhibit tumor growth. |
| Targets&IC50 | KRas (G12C):1.6 nM |
| In vivo | Methods: Glecirasib (10 mg/kg, oral, once a day, 3 weeks) was used to treat NCI-H1373 xenograft mice, and the tumor growth and body weight growth in the mice were observed. Results: Glecirasib inhibited tumor growth in the NCI-H1373 xenograft mouse model and had no significant effect on the body weight of the mice, indicating high safety. [1-3] |
| Synonyms | KRAS G12C inhibitor 36, JAB-21822, JAB21822, JAB-21000, JAB21000 |
| Molecular Weight | 640.03 |
| Formula | C31H26ClF4N7O2 |
| Cas No. | 2657613-87-9 |
| Smiles | N#CC=1C(=O)N(C=2N=C(C(Cl)=CC2C1N3CCN(C(=O)C=C)CC3)C=4C(F)=C(F)C(F)=C(F)C4N)C=5C(=NC=CC5C)C(C)C |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.